Clinical trials: Chronic Plaque Psoriasis
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
- Trial name
- NCT03000075
- Testing
- risankizumab
- Volunteers
- 182 people
- Sponsor
- AbbVie
Moderate-to-severe Chronic Plaque Psoriasis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT07362017
- Testing
- Ponesimod
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vanda Pharmaceuticals
Chronic Plaque Psoriasis
Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients
An open-label, multicentre study to evaluate the efficacy and safety of one course of weekly intramuscular administration of Amevive in Taiwan patients with chronic plaque psoriasis
- Trial name
- NCT00422617
- Testing
- Alefacept (Amevive)
- Volunteers
- 40 people
- Sponsor
- Uni-Pharma
Psoriasis
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to…
- Trial name
- SIGNATURE (NCT01961609)
- Testing
- Secukinumab (AIN457)
- Where
- 54 sites in Ireland, United Kingdom
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis.
- Trial name
- NCT00147329
- Testing
- MM-093
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merrimack Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- reSURFACE 2 (NCT01729754)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg, Etanercept 50 mg
- Volunteers
- 1,090 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Psoriasis
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
The primary objective of this study will be to evaluate the efficacy of topical ALT-2074 applied twice daily for 28 days for treatment of chronic plaque psoriasis in adult subjects.
- Trial name
- NCT00782613
- Testing
- 4,4-dimethyl-benziso-2H-selenazine
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Synvista Therapeutics, Inc
Plaque Psoriasis
LAS41008 in Moderate to Severe Chronic Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01726933
- Testing
- LAS41008, LASW1835
- Where
- 4 sites in Austria, Germany and 2 more
- Volunteers
- 839 people
- Sponsor
- Almirall, S.A.
Chronic Plaque Psoriasis
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for…
- Trial name
- NCT02852967
- Testing
- Belumosudil
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Kadmon Corporation, LLC
Psoriasis
Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis
This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of follow-up. The purpose of the study is to compare the safety and effectiveness of combining and then following a high potency topical…
- Trial name
- NCT00769184
- Testing
- Corticosteroid, LCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NeoStrata Company, Inc.
Plaque Psoriasis
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Trial name
- NCT00691964
- Testing
- ABT-874, etanercept
- Where
- 35 sites in United States
- Volunteers
- 347 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health…
- Trial name
- NCT04818385
- Where
- 8 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
- Trial name
- NCT03897075
- Testing
- Tildrakizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 99 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Psoriasis
Study in Patients With Mild to Moderate Psoriasis
This was a randomized, double blind,fixed dose, placebo controlled, parallel-group pilot study to obtain data on size and variance of treatment effects in subjects with mild to moderate Psoriasis.
- Trial name
- AH-PSR-01 (NCT01451346)
- Testing
- B. Infantis 35624
- Where
- Ireland
- Volunteers
- 47 people
- Sponsor
- Alimentary Health Ltd
Psoriasis
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
REALIZE study will include a representative sample of 500 patients with moderate to severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label…
- Trial name
- REALIZE (NCT03757013)
- Testing
- Apremilast
- Where
- 93 sites in France
- Volunteers
- 453 people
- Sponsor
- Amgen
Psoriasis
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis
- Trial name
- NCT04930042
- Testing
- Stelara, AVT04
- Where
- 30 sites in Estonia, Georgia and 2 more
- Volunteers
- 581 people
- Sponsor
- Alvotech Swiss AG
Psoriasis
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00679731
- Testing
- ABT-874, Methotrexate
- Where
- 43 sites in Austria, Belgium and 12 more
- Volunteers
- 317 people
- Sponsor
- AbbVie (prior sponsor, Abbott)